Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Last updated: February 28, 2025
Sponsor: Novartis Pharmaceuticals
Overall Status: Active - Recruiting

Phase

2/3

Condition

Urologic Cancer

Prostate Cancer

Prostate Cancer, Early, Recurrent

Treatment

AAA817

Investigators choice of SoC

Clinical Study ID

NCT06780670
CAAA817A12201
2024-512342-42-00
  • Ages 18-100
  • Male

Study Summary

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.

Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Eligibility Criteria

Inclusion

Inclusion Criteria: ∙

  • adults ≥ 18 years of age.

  • ECOG performance status of 0 to 2.

  • histopathological and/or cytological confirmation of adenocarcinoma of the prostate.

  • PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imagingagent as protocol instructed,

  • castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).

  • Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-basedchemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy.

  • ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scanimaging obtained ≤ 28 days prior to randomization

  • eGFR as requested by the sponsor

Exclusion

Exclusion Criteria:

  • Any investigational agents within 28 days prior to the day of randomization.

  • Any 225Ac-based investigational compound used prior to the day of randomization.

  • Participants with a history of CNS metastases who are neurologically unstable,symptomatic, or receiving corticosteroids for the purpose of maintaining neurologicintegrity.

  • Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days)or chronic kidney disease (at least 3 months of ongoing renal injury)

  • Baseline xerostomia ≥ Grade 2 by CTCAE v.5

  • History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris,or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/orclinically active significant cardiac disease

  • History of lymphoproliferative disease or any known malignancy or history ofmalignancy of any organ system within the past 5 years (except for basal cellcarcinoma or actinic keratosis that have been treated with no evidence of recurrencein the past 3 months, non-invasive malignant colon polyps that have been removed).

Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Total Participants: 432
Treatment Group(s): 2
Primary Treatment: AAA817
Phase: 2/3
Study Start date:
February 27, 2025
Estimated Completion Date:
May 31, 2033

Study Description

Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.

Connect with a study center

  • Novartis Investigative Site

    Singapore, 168583
    Singapore

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.